Peter Michael Smith

Title: Innovations in Cancer Treatment by Peter Michael Smith

Introduction

Peter Michael Smith is a notable inventor based in London, GB. He has made significant contributions to the field of cancer treatment through his innovative research and inventions. With a total of 3 patents, Smith's work focuses on utilizing human prostate cell lines for immunotherapy in cancer treatment.

Latest Patents

Smith's latest patents include groundbreaking inventions related to the use of human prostate cell lines in cancer treatment. One of his key inventions involves a product comprised of cell lines intended for use as an allogeneic immunotherapy agent for treating cancer in mammals and humans. This invention challenges the conventional approach of using tumor cells, as it emphasizes the effectiveness of immortalized normal, non-malignant cells as the basis for an allogeneic cell cancer vaccine. The surprising efficacy of these normal cells as anti-cancer vaccines opens new avenues for prostate cancer treatment. The cell lines are lethally irradiated using gamma irradiation at 50-300 Gy to ensure they are replication incompetent prior to use in patients.

Career Highlights

Peter Michael Smith is associated with Onyvax Limited, where he continues to advance his research in cancer immunotherapy. His work has garnered attention for its innovative approach to utilizing normal cells in cancer vaccines, which could potentially revolutionize treatment methods.

Collaborations

Some of his notable coworkers include Andrew Derek Sutton and Angus Dalgleish, who contribute to the collaborative efforts in research and development at Onyvax Limited.

Conclusion

Peter Michael Smith's innovative work in cancer treatment through the use of human prostate cell lines represents a significant advancement in the field. His contributions have the potential to change the landscape of cancer immunotherapy, offering new hope for patients.